Table 1.
Experimental design of the preliminary research.
| Group | n | Time | ||
|---|---|---|---|---|
| −0.5 h | 0 h | 12 h | ||
| Sham-operated group | 8 | Vehicle (10% DMSO) | Saline | Sacrifice |
| Acute necrotizing pancreatitis group | 8 | Vehicle (10% DMSO) | Taurocholate | Sacrifice |
| Zerumbone pretreated group 5 mg/kg | 8 | Zerumbone 5 mg/kg | Taurocholate | Sacrifice |
| Zerumbone pretreated group 10 mg/kg | 8 | Zerumbone 10 mg/kg | Taurocholate | Sacrifice |
| Zerumbone pretreated group 20 mg/kg | 8 | Zerumbone 20 mg/kg | Taurocholate | Sacrifice |
| Zerumbone pretreated group 40 mg/kg | 8 | Zerumbone 40 mg/kg | Taurocholate | Sacrifice |
In acute necrotizing pancreatitis group, rats received the vehicle (10% DMSO, 2 mL/kg) administered via femoral vein half an hour prior to retrograde infusion of a freshly prepared 5% sodium taurocholate solution (1 mg/kg). In sham-operated group, rats received the vehicle administered via femoral vein and after half an hour, the rats were retrograde infused isotonic saline solution (1 mL/kg). In zerumbone pretreated group, rats received 5, 10, 20, and 40 mg/kg zerumbone dissolved in vehicle (10% DMSO v/v) administered via femoral vein half an hour prior to infusion 5% sodium taurocholate solution (1 mg/kg).